Arrowhead Pharmaceuticals Faces Pivotal FDA Verdict on Key Drug

Investor attention is firmly fixed on Arrowhead Pharmaceuticals as the company approaches a critical regulatory milestone. Within days, the U.S. Food and Drug Administration will deliver its verdict on Plozasiran, a potentially transformative RNA interference therapy for familial chylomicronemia. This decision represents the most significant test for the biotech firm this year, with market analysts increasingly optimistic about the outcome.

Arrowhead has strategically fortified its financial position through collaborations with major pharmaceutical players. A landmark agreement with Novartis delivered an immediate $200 million payment, with potential milestone payments reaching $2 billion for the Parkinson's disease treatment ARO-SNCA. Previously, the company's partnership with Sarepta Therapeutics generated $825 million in funding. These substantial capital infusions provide financial stability through 2028, allowing continued development of Arrowhead's drug pipeline regardless of immediate regulatory outcomes.

Wall Street Confidence Surges

Market sentiment toward Arrowhead has strengthened considerably, evidenced by Morgan Stanley's recent analysis. While maintaining an "Equal-Weight" rating, the investment bank dramatically increased its price target from $29 to $45 per share—representing a 55% upward revision. This substantial adjustment signals growing institutional confidence in the company's prospects and has contributed to the stock's impressive performance throughout the year.

Should investors sell immediately? Or is it worth buying Arrowhead?

Plozasiran's Clinical Promise and Market Potential

The FDA's decision on Plozasiran, scheduled for November 18, 2025, carries enormous significance for patients and investors alike. Clinical trial results demonstrated exceptional efficacy, with an 80% reduction in triglyceride levels compared to placebo. More notably, the therapy showed an 83% risk reduction for acute pancreatitis events. If approved, Plozasiran could revolutionize treatment for severe hypertriglyceridemia, addressing significant limitations of existing therapies that often prove inadequate for many patients.

Investor Focus Intensifies Ahead of Catalysts

Arrowhead shares have delivered remarkable gains, advancing more than 87% since January and trading near their 52-week peak. The company remains in the investment spotlight with quarterly earnings scheduled for November 25 and multiple medical conferences planned throughout the month. However, these events may be overshadowed by the impending FDA ruling that will ultimately determine whether Arrowhead fulfills its promise as a biotechnology leader or disappoints elevated market expectations.